Idiopathic Pulmonary Fibrosis Market provides analysis of the current Industry Situation and Strategies Focuses for Finds future growth of Business

The market for idiopathic pulmonary fibrosis is expected to grow at an average annual rate of 11.9% from 2013 to 2023, reaching $ 3,569 million by 2023. Perifenidone occupied more than half of the entire market in 2016.
Idiopathic pulmonary fibrosis is a disease in which pulmonary tissue becomes thicker and harder over time, decreasing the ability of the tissue to carry oxygen.

The increase in the elderly population and the increase in patients suffering from idiopathic pulmonary fibrosis are expected to stimulate market growth. In addition, the growth of cigarette smoking increases the growth of the market. However, if treatment options that can completely cure the disease become unavailable, market growth will be limited.
Perifenidone is expected to dominate the market throughout the analysis period as it helps slow the scarring and preserve lung function. Nintedanib is expected to grow at a CAGR of 12.2% over the forecast period.

Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/4407

The major companies profiled in the report include
• MediciNova Inc.
• Boehringer Ingelheim
• F. Hoffmann-La Roche
• FibroGen Inc.
• Promedior Inc.
• Merck & Co. Inc.
• Galapagos NV
• Biogen
• Bristol-Myers Squibb Company
• Prometic Life Sciences Inc.
• Cipla Inc.

Asia-Pacific is projected to register the highest CAGR of 13.0% during the forecast period, owing to increase in incidence of population suffering from fibrotic disease and rise in ageing population. In addition, increase in healthcare expenditure offers a lucrative opportunity for the market growth.

Make an Enquiry before Buy @ https://www.alliedmarketresearch.com/purchase-enquiry/4407

Key Findings of the Idiopathic Pulmonary Fibrosis Market:
• Nintedanib is projected to grow at a CAGR of 12.2% during the forecast period.
• Pirfenidone accounted for more than half of the share of the global idiopathic pulmonary fibrosis market in 2016.
• France and Germany collectively contributed for more than one-third share of the European idiopathic pulmonary fibrosis market in 2016.
• Japan was the major shareholder in 2016, accounting for more than one-third share of the Asia-Pacific idiopathic pulmonary fibrosis market.
• Brazil is the major shareholder in 2016, accounting for nearly than one-fourth share of the LAMEA idiopathic pulmonary fibrosis market.

Access Full Summery @ https://www.alliedmarketresearch.com/idiopathic-pulmonary-fibrosis-market

About Us:

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Contact:

David Correa

5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States

Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975

help@alliedmarketresearch.com

This release was published on openPR.